Cancer Genetics Inc. (NASDAQ:CGIX)’s share price traded up 2.5% during mid-day trading on Thursday . The company traded as high as $2.16 and last traded at $2.08, with a volume of 106,428 shares traded. The stock had previously closed at $2.03.

Separately, Zacks Investment Research upgraded Cancer Genetics from a “hold” rating to a “buy” rating and set a $2.50 price target on the stock in a report on Wednesday, May 11th.

The stock has a 50-day moving average price of $2.14 and a 200-day moving average price of $2.31. The firm’s market cap is $33.53 million.

Cancer Genetics (NASDAQ:CGIX) last released its quarterly earnings results on Wednesday, August 10th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.05. The business earned $7 million during the quarter, compared to analysts’ expectations of $6.50 million. The business’s revenue was up 67.3% on a year-over-year basis. During the same period in the previous year, the business earned ($0.51) EPS. On average, equities analysts anticipate that Cancer Genetics Inc. will post ($1.19) earnings per share for the current fiscal year.

In other news, Director John Pappajohn acquired 45,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 16th. The shares were bought at an average cost of $2.29 per share, with a total value of $103,050.00. Following the acquisition, the director now owns 2,287,109 shares in the company, valued at approximately $5,237,479.61. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Cancer Genetics, Inc is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services, and molecular markers. The Company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.